Pregnancy: Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using atorvastatin. Discuss future pregnancy plans with patients, and discuss when to stop atorvastatin if patients are trying to conceive. Patients who become pregnant should be advised to stop taking atorvastatin and call their healthcare professional.
Breastfeeding: Women who are breastfeeding should be advised to not use atorvastatin. Patients who have a lipid disorder and are breastfeeding, should be advised to discuss the options with their healthcare professional.
Atorvastatin is contraindicated in pregnancy and while breast-feeding. Women of child-bearing potential should use appropriate contraceptive measures.
An interval if 1 month should be allowed from stopping Atorvastatin treatment to conception in the event of planning a pregnancy.
In animal studies, atorvastatin had no effect on fertility and was not teratogenic, however, at maternally toxic doses, foetal toxicity was observed in rats and rabbits. The development of the rat offspring was delayed and post-natal survival reduced during exposure of the dams to atorvastatin equivalent to 6 and 21 times that expected in man, respectively.
It is not known whether this drug or its metabolites is excreted in human milk.